Why the study?
Do platelets from CAD patients exhibit higher reactivity and adhesion to polymer-based biomaterials compared to platelets from healthy individuals?
Do platelets from CAD patients exhibit higher reactivity and adhesion to polymer-based biomaterials compared to platelets from healthy individuals?
Standard hemocompatibility testing using healthy donor platelets may underestimate the thrombogenicity of biomaterials intended for CAD patients.
Standard hemocompatibility testing with healthy platelets may underestimate CAD thrombogenicity; leaves open human validation of patient-specific assays.
On the basis of the clinical studies in patients with coronary artery disease (CAD) presenting an increased percentage of activated platelets, we hypothesized that hemocompatibility testing utilizing platelets from healthy individuals may result in an underestimation of the materials' thrombogenicity. Therefore, we investigated the interaction of polymer-based biomaterials with platelets from CAD patients in comparison to platelets from apparently healthy individuals. In vitro static thrombogenicity tests revealed that adherent platelet densities and total platelet covered areas were significantly increased for the low (polydimethylsiloxane, PDMS) and medium (Collagen) thrombogenic surfaces in the CAD group compared to the healthy subjects group. The area per single platelet-indicating the spreading and activation of the platelets-was markedly increased on PDMS treated with PRP from CAD subjects. This could not be observed for collagen or polytetrafluoroethylene (PTFE). For the latter material, platelet adhesion and surface coverage did not differ between the two groups. Irrespective of the substrate, the variability of these parameters was increased for CAD patients compared to healthy subjects. This indicates a higher reactivity of platelets from CAD patients compared to the healthy individuals. Our results revealed, for the first time, that utilizing platelets from apparently healthy donors bears the risk of underestimating the thrombogenicity of polymer-based biomaterials.
No takes yet. Share an insight, caveat, or question.
Braune et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: